Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice-Reference-Cited by-同舟云学术

Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice

Published:2020-05-25 Issue:10 Volume:61 Page:2383-2388
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Koehler Amber B.¹,Leung Nelson²^ORCID,Call Timothy G.¹,Rabe Kari G.³,Achenbach Sara J.³,Ding Wei¹,Kenderian Saad S.¹,Leis Jose F.⁴,Wang Yucai¹,Muchtar Eli¹^ORCID,Hayman Suzanne R.¹,Hampel Paul J.¹^ORCID,Finnes Heidi D.⁵,Schwager Susan M.³,Slager Susan L.³,Kay Neil E.¹,Parikh Sameer A.¹^ORCID

Affiliation:

1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;

2. Division of Nephrology, Mayo Clinic, Rochester, MN, USA;

3. Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA;

4. Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA;

5. Department of Pharmacy Cancer Care, Mayo Clinic, Rochester, MN, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1768384